Oncology
Merck Serono focuses on developing novel, cancer-specific therapies that provide beneficial therapeutic outcomes and create
new options for cancer patients.
Our monoclonal antibody, Erbitux, specifically blocks the epidermal growth factor receptor (EGFR) to enhance the effect of
chemotherapy and radiotherapy.
